Inflammatory Biomarkers and Mortality Risk Among HIV-Suppressed Men: A Multisite Prospective Cohort Study

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2016 Jun 26

PMID 27343547

Citations 47

Authors

Nikolas I Wada

Jay H Bream

Otoniel Martinez-Maza

Bernard Macatangay

Shannon R Galvin

Joseph B Margolick

Lisa P Jacobson

Affiliations

Soon will be listed here.

Abstract

Background: Human immunodeficiency virus (HIV)-induced inflammation and immune activation persist after initiation of combination antiretroviral therapy (cART) and HIV suppression and may contribute to mortality risks that exceed those in HIV-uninfected populations, though associations are unclear.

Methods: In the prospective Multicenter AIDS Cohort Study, comprising men who have sex with men from Baltimore, Chicago, Los Angeles, and Pittsburgh, concentrations of 24 biomarkers of inflammation and immune activation were measured in stored serum from HIV-positive men obtained after cART-induced HIV suppression between 1996 and 2009. The outcome was nonaccidental death, with follow-up until 2014. We used Cox proportional hazards models to test whether biomarker concentrations predict time from HIV suppression to death and adjusted for multiple tests. Exploratory factor analysis (EFA) was employed to identify groupings of biomarkers that predict mortality risk.

Results: Of 670 men followed up from HIV suppression, 54 died by the end of 2013. After adjustment for age, CD4(+) cell count, hepatitis B or C virus infection, and smoking, concentrations in the highest quartile of 4 biomarkers were significantly associated with mortality risk after controlling the false discovery rate at 5%: interleukin (IL) 6 (hazard ratio, 3.54; 95% confidence interval, 2.06-6.10), soluble IL 2Rα (3.29, 1.85-5.85), soluble CD14 (2.67, 1.55-4.61), and chemokine (CXC motif) ligand 13 (CXCL13; 2.26; 1.29-3.95). EFA yielded 2 biomarker groupings that were independent predictors of mortality risk.

Conclusions: Despite having undetectable HIV RNA levels during cART, men with higher concentrations of several biomarkers (particularly IL 6, soluble IL 2Rα, soluble CD14, and CXCL13) had higher hazards of long-term mortality. Correlations observed among biomarker concentrations may represent underlying inflammatory processes that contribute to mortality risk.

Citing Articles

Proinflammatory Biomarkers and Clinical Factors Associated with Long-Term Mortality in People with HIV.

Lembas A, Zaleski A, Mikula T, Kozlowska J, Wiercinska-Drapalo A Viruses. 2025; 17(2).

PMID: 40006998 PMC: 11860511. DOI: 10.3390/v17020243.

Association between cytokine and increased risk of death in ART- naïve and ART-non-adherence patients hospitalized with advanced HIV disease.

Chaves Y, Gama W, Reis M, Baptista B, Almeida T, Balieiro A BMC Infect Dis. 2025; 25(1):197.

PMID: 39924485 PMC: 11808995. DOI: 10.1186/s12879-024-10260-z.

HIV and Inflamm-Aging: How Do We Reach the Summit of Healthy Aging?.

Sheets K, Baker J Top Antivir Med. 2025; 32(5):589-596.

PMID: 39765238 PMC: 11737810.

Innate immune memory in chronic HIV and HIV-associated neurocognitive disorders (HAND): potential mechanisms and clinical implications.

Capriotti Z, Klase Z J Neurovirol. 2024; 30(5-6):451-476.

PMID: 39733092 PMC: 11846772. DOI: 10.1007/s13365-024-01239-2.

Early inflammation as a footprint of increased mortality risk in infants living with HIV from three African countries.

Morrocchi E, Pascucci G, Cotugno N, Pighi C, Dominguez-Rodriguez S, Petrara M Sci Rep. 2024; 14(1):25792.

PMID: 39468166 PMC: 11519903. DOI: 10.1038/s41598-024-74066-4.

References

Wada N, Jacobson L, Cohen M, French A, Phair J, Munoz A . Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol. 2013; 177(2):116-25. PMC: 3590031. DOI: 10.1093/aje/kws321. View

Sandler N, Wand H, Roque A, Law M, Nason M, Nixon D . Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011; 203(6):780-90. PMC: 3071127. DOI: 10.1093/infdis/jiq118. View

Lederman M, Funderburg N, Sekaly R, Klatt N, Hunt P . Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013; 119:51-83. PMC: 4126613. DOI: 10.1016/B978-0-12-407707-2.00002-3. View

Achenbach C, Buchanan A, Cole S, Hou L, Mugavero M, Crane H . HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis. 2014; 58(11):1599-606. PMC: 4017888. DOI: 10.1093/cid/ciu076. View

Andrade B, Hullsiek K, Boulware D, Rupert A, French M, Ruxrungtham K . Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis. 2013; 207(9):1379-88. PMC: 3610421. DOI: 10.1093/infdis/jit033. View

Visconti L, Nelissen K, Deckx L, van den Akker M, Adriaensen W, Daniels L . Prognostic value of circulating cytokines on overall survival and disease-free survival in cancer patients. Biomark Med. 2014; 8(2):297-306. DOI: 10.2217/bmm.13.122. View

Tenorio A, Zheng Y, Bosch R, Krishnan S, Rodriguez B, Hunt P . Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014; 210(8):1248-59. PMC: 4192039. DOI: 10.1093/infdis/jiu254. View

Kaslow R, Ostrow D, Detels R, Phair J, Polk B, Rinaldo Jr C . The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987; 126(2):310-8. DOI: 10.1093/aje/126.2.310. View

Tien P, Choi A, Zolopa A, Benson C, Tracy R, Scherzer R . Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010; 55(3):316-22. PMC: 2955817. DOI: 10.1097/QAI.0b013e3181e66216. View

10.

Kishimoto T . IL-6: from its discovery to clinical applications. Int Immunol. 2010; 22(5):347-52. DOI: 10.1093/intimm/dxq030. View

11.

Thio C, Seaberg E, Skolasky Jr R, Phair J, Visscher B, Munoz A . HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002; 360(9349):1921-6. DOI: 10.1016/s0140-6736(02)11913-1. View

12.

Wada N, Jacobson L, Margolick J, Breen E, Macatangay B, Penugonda S . The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015; 29(4):463-71. PMC: 4311407. DOI: 10.1097/QAD.0000000000000545. View

13.

Wada N, Jacobson L, Cohen M, French A, Phair J, Munoz A . Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS. 2013; 28(2):257-65. PMC: 4164055. DOI: 10.1097/QAD.0000000000000078. View

14.

Grulich A, van Leeuwen M, Falster M, Vajdic C . Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 370(9581):59-67. DOI: 10.1016/S0140-6736(07)61050-2. View

15.

Hunt P, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N . Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014; 210(8):1228-38. PMC: 4192038. DOI: 10.1093/infdis/jiu238. View

16.

Phillips A, Neaton J, Lundgren J . The role of HIV in serious diseases other than AIDS. AIDS. 2008; 22(18):2409-18. PMC: 2679976. DOI: 10.1097/QAD.0b013e3283174636. View

17.

Breen E, Rezai A, Nakajima K, Beall G, Mitsuyasu R, Hirano T . Infection with HIV is associated with elevated IL-6 levels and production. J Immunol. 1990; 144(2):480-4. View

18.

Kalayjian R, Machekano R, Rizk N, Robbins G, Gandhi R, Rodriguez B . Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010; 201(12):1796-805. PMC: 2873127. DOI: 10.1086/652750. View

19.

French M, King M, Tschampa J, da Silva B, Landay A . Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009; 200(8):1212-5. DOI: 10.1086/605890. View

20.

Albert C, Ma J, Rifai N, Stampfer M, Ridker P . Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002; 105(22):2595-9. DOI: 10.1161/01.cir.0000017493.03108.1c. View